Photodynamic therapy with aminolevulinic acid and blue light is used in Europe for basal cell carcinoma (BCC), but not in the United States due to uncertainties about efficacy. To potentially improve treatment outcomes and make PDT a more attractive as therapy for BCC, we conducted a prospective, double-blind, crossover clinical trial to test whether pretreatment with oral Vitamin D may enhance BCC responses to blue light PDT. Three separate PDT sessions were administered, with patients receiving daily doses of Vitamin D (10,000 units) or placebo for a week prior to PDT. We will report here on interim clinical trial outcomes.
|